期刊文献+

解毒利咽法防治IgA肾病进展的临床研究 被引量:2

Clinical Study of Jiedu Liyan Therapy in Preventing and Treating IgA Nephropathy
下载PDF
导出
摘要 目的:观察清咽解毒茶防治IgA肾病进展的有效性及安全性。方法:采用随机对照法,将符合临床标准的患者随机分为治疗组及对照组,治疗组采用基础治疗及清咽解毒茶治疗,对照组采用基础治疗,验证清咽解毒茶防治IgA肾病毒聚咽喉证的有效性及安全性。通过观察中医证候积分、肾功能、肾小球滤过率、24 h尿蛋白定量、尿常规等评价疗效。结果:与对照组比较,治疗组临床症状减轻(P<0.01),血尿、蛋白尿减少(P<0.05),治疗组总有效率93.5%(29/31),显著高于对照组73.3%(22/30)(P<0.01)。治疗组肾功能有所改善,但与对照组差异无统计学意义。结论:清咽解毒茶联合基础治疗对IgA肾病毒聚咽喉证有较好疗效。 Objective:To observe the efficacy and safety of Qingyan Jiedu Tea in the prevention and treatment of IgA nephropathy.Methods:Patients meeting the clinical standards were randomly divided into the treatment group and the control group.The control group was treated with basic treatment;on which basis,the treatment group was also treated with Qingyan Jiedu Tea.The effectiveness and safety of Qingyan Jiedu Tea were verified in the prevention and treatment of polytoxic throat syndrome of IgA nephropathy.The efficacy was evaluated by observing TCM syndrome integral,renal function,glomerular filtration rate,24-hour urinary protein quantification and urine routine.Results:The clinical symptoms were significantly alleviated(P<0.01),hematuria and proteinuria were reduced in the treatment group compared to those in the control group after the treatment(P<0.05).The total effective rate of the treatment group was 93.5%(29/31),which was significantly higher than 73.3%(22/30)of the control group(P<0.01).The renal function was improved in the treatment group,of which there was no statistical difference between the treatment group and the control group.Conclusion:Qingyan Jiedu Tea combined with basic therapy has a good effect on polytoxic throat syndrome of IgA nephropathy.
作者 邹迪 张守琳 张洪宝 ZOU Di;ZHANG Shoulin;ZHANG Hongbao(Affiliated Hospital of Changchun University of Chinese Medicine,Changchun 130021,China)
出处 《中医药学报》 CAS 2021年第12期72-75,共4页 Acta Chinese Medicine and Pharmacology
基金 国家重点研发计划课题(2019YFC1709903) 吉林省科技厅资助项目(20190201029JC) 吉林省中医药科技项目(2020062)。
关键词 清咽解毒茶 IGA肾病 临床研究 Qingyan Jiedu Tea IgA nephropathy Clinical research
  • 相关文献

参考文献9

二级参考文献50

  • 1陈香美,陈以平,李平,陈建,谌贻璞,周柱亮,陈威,赵宗江,危成筠,魏日胞,邓跃毅,李建军,杜婧,周瑾,何亚妮.1016例IgA肾病患者中医证候的多中心流行病学调查及相关因素分析[J].中国中西医结合杂志,2006,26(3):197-201. 被引量:236
  • 2陈香美,陈建,陈以平,周柱亮,何亚妮,李平,魏日胞,邓跃毅,赵宗江,危成筠,李建军,杜婧.肾华片治疗IgA肾病(气阴两虚证)多中心随机对照临床观察[J].中国中西医结合杂志,2007,27(2):101-105. 被引量:58
  • 3聂莉芳.IgA肾病的诊断、辨证分型和疗效评定(试行方案)[J].上海中医药杂志,2007,41(5):9-10. 被引量:110
  • 4陈香美.临床诊疗指南肾脏病学分册[M].北京:人民卫生出版社,2011:58-66.
  • 5Kidney Disease : Improving Global Outcomes (KDIGO) Glomerulo- nephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis [ J 1. Kidney Int,2012, Suppl ( 2 ) : 139 - 274.
  • 6Reich HN,Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgAN [ J ]. J Am Soc lephrol,2007,18 ( 12 ) : 3177 -3183.
  • 7Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy : rationale, clinicopathological correlations, and clas- sification [ J 1- Kidney Int 2009,76 (5) :534 - 545.
  • 8Praga M, Gutierrez E, Gonzalez E, et al. Treatment of IgAN with ACE inhibitors: A randomized and controlled trial [ J ]. J Am Soc Nephro1,2003,14 ( 6 ) : 1578 - 1583.
  • 9Li PKT, Leung CB, Chow KM, ct al. Hong Kong study using Valsar- tan in IgAN (HKVIN)- A double-blind randomized placebo-con- trolled study[ J l. Am J Kidney Dis,2006,47 (5) :751 -760.
  • 10Coppo R, Peruzzi L, Amorc A, ctal. IgACE : a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in chil- dren and young people with IgAN and moderate protcinuria [ J ]. J Am Soc Nephrol,2007,18 (6) : 1880 - 1888.

共引文献310

同被引文献31

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部